185 related articles for article (PubMed ID: 20919746)
21. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels.
Hendriks BS; Opresko LK; Wiley HS; Lauffenburger D
J Biol Chem; 2003 Jun; 278(26):23343-51. PubMed ID: 12686539
[TBL] [Abstract][Full Text] [Related]
22. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
23. A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization.
Kanthala SP; Liu YY; Singh S; Sable R; Pallerla S; Jois SD
Oncotarget; 2017 Sep; 8(43):74244-74262. PubMed ID: 29088782
[TBL] [Abstract][Full Text] [Related]
24. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
Bello M; Saldaña-Rivero L; Correa-Basurto J; García B; Sánchez-Espinosa VA
Int J Biol Macromol; 2018 May; 111():569-586. PubMed ID: 29329808
[TBL] [Abstract][Full Text] [Related]
25. Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells.
Kanthala S; Mill CP; Riese DJ; Jaiswal M; Jois S
Protein Expr Purif; 2016 Sep; 125():26-33. PubMed ID: 26363121
[TBL] [Abstract][Full Text] [Related]
26. Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases.
Shih AJ; Telesco SE; Choi SH; Lemmon MA; Radhakrishnan R
Biochem J; 2011 Jun; 436(2):241-51. PubMed ID: 21426301
[TBL] [Abstract][Full Text] [Related]
27. Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors.
Geng L; Wang Z; Yang X; Li D; Lian W; Xiang Z; Wang W; Bu X; Lai W; Hu Z; Fang Q
Theranostics; 2015; 5(10):1154-65. PubMed ID: 26284145
[TBL] [Abstract][Full Text] [Related]
28. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research.
Earp HS; Dawson TL; Li X; Yu H
Breast Cancer Res Treat; 1995 Jul; 35(1):115-32. PubMed ID: 7612898
[TBL] [Abstract][Full Text] [Related]
29. Biology of HER2 and its importance in breast cancer.
Yarden Y
Oncology; 2001; 61 Suppl 2():1-13. PubMed ID: 11694782
[TBL] [Abstract][Full Text] [Related]
30. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
Kong A; Calleja V; Leboucher P; Harris A; Parker PJ; Larijani B
PLoS One; 2008 Aug; 3(8):e2881. PubMed ID: 18682844
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor ligands as new extracellular targets for the metastasis-promoting S100A4 protein.
Klingelhöfer J; Møller HD; Sumer EU; Berg CH; Poulsen M; Kiryushko D; Soroka V; Ambartsumian N; Grigorian M; Lukanidin EM
FEBS J; 2009 Oct; 276(20):5936-48. PubMed ID: 19740107
[TBL] [Abstract][Full Text] [Related]
32. Dynamical Rearrangement of Human Epidermal Growth Factor Receptor 2 upon Antibody Binding: Effects on the Dimerization.
Magalhães PR; Machuqueiro M; Almeida JG; Melo A; D S Cordeiro MN; Verde SC; Gümüş ZH; Moreira IS; D G Correia J; Melo R
Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31694351
[TBL] [Abstract][Full Text] [Related]
33. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
Cho HS; Mason K; Ramyar KX; Stanley AM; Gabelli SB; Denney DW; Leahy DJ
Nature; 2003 Feb; 421(6924):756-60. PubMed ID: 12610629
[TBL] [Abstract][Full Text] [Related]
34.
Shrestha L; Singh SS; Parajuli P; Dahal A; Mattheolabakis G; Meyer S; Bhattacharjee J; Jois SD
J Cancer; 2020; 11(20):5982-5999. PubMed ID: 32922539
[TBL] [Abstract][Full Text] [Related]
35. Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer.
Kanthala S; Banappagari S; Gokhale A; Liu YY; Xin G; Zhao Y; Jois S
Chem Biol Drug Des; 2015 Jun; 85(6):702-714. PubMed ID: 25346057
[TBL] [Abstract][Full Text] [Related]
36. Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling.
Menendez JA; Schroeder B; Peirce SK; Vellon L; Papadimitropoulou A; Espinoza I; Lupu R
J Natl Cancer Inst; 2015 Jun; 107(6):djv090. PubMed ID: 25888715
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.
Paris L; Cecchetti S; Spadaro F; Abalsamo L; Lugini L; Pisanu ME; Iorio E; Natali PG; Ramoni C; Podo F
Breast Cancer Res; 2010; 12(3):R27. PubMed ID: 20462431
[TBL] [Abstract][Full Text] [Related]
38. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
Bouyain S; Longo PA; Li S; Ferguson KM; Leahy DJ
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15024-9. PubMed ID: 16203964
[TBL] [Abstract][Full Text] [Related]
39. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
[TBL] [Abstract][Full Text] [Related]
40. Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers.
Choi B; Cha M; Eun GS; Lee DH; Lee S; Ehsan M; Chae PS; Heo WD; Park Y; Yoon TY
Elife; 2020 Apr; 9():. PubMed ID: 32267234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
